GlassScriptPhysician profile
Hongyan Liang
NPI 1194931568
$2,323.63
in general payments reported to CMS, 2019-2025
40 companies · $912 in 2025
The $912 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $182 · 2021: $15.67 · 2023: $388 · 2024: $635 · 2025: $912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,794 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,793.55 |
| Education | $141.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $263.90 | 2020-2025 | Enhertu, Imfinzi, Lynparza |
| Daiichi Sankyo INC. | $182.30 | 2023-2025 | Enhertu, Injectafer, Vanflyta |
| Genzyme Corporation | $179.90 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $151.78 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Novartis Pharmaceuticals Corporation | $140.98 | 2019-2025 | |
| Myriad Genetic Laboratories, INC. | $121.87 | 2023-2024 | Myrisk |
| Gilead Sciences, INC. | $95.95 | 2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $88.83 | 2023-2025 | |
| Eisai INC. | $71.78 | 2020-2025 | |
| Amgen INC. | $71.28 | 2019-2020 | |
| Abbvie INC. | $67.60 | 2019-2025 | |
| Pfizer INC. | $63.38 | 2023-2025 | |
| Array Biopharma INC | $63.37 | 2024 | Mektovi, Braftovi, Lorbrena |
| Stemline Therapeutics INC. | $61.82 | 2023-2025 | Orserdu |
| Ipsen Biopharmaceuticals, INC | $56.31 | 2024-2025 | Onivyde |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hongyan Liang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.